Compare VTGN & DFLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTGN | DFLI |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | 141 |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 25.1M |
| IPO Year | 2014 | N/A |
| Metric | VTGN | DFLI |
|---|---|---|
| Price | $0.26 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $0.90 | ★ $3.25 |
| AVG Volume (30 Days) | ★ 4.0M | 355.3K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | $51.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.15 |
| 52 Week High | $5.14 | $5.15 |
| Indicator | VTGN | DFLI |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 41.94 |
| Support Level | $0.20 | $1.67 |
| Resistance Level | $0.66 | $2.25 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 10.27 | 9.37 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.